Reverb Therapeutics
Reverb is a seed-stage oncology company with a highly differentiated platform approach to cytokine therapy. Its Amplifier™ platform uses bispecific antibodies to localize endogenous cytokines to immune cells in the tumor microenvironment (TME) and overcome toxicity issues of exogenously delivered cytokines. Instead of using heavily engineered exogenous cytokines to treat diseases, which present challenges such as systemic toxicity and immunogenicity, Reverb’s antibodies redirect endogenous cytokines already in the body to cells of interest.